Reza Dana

The Schepens Eye Research Institute, Inc. operates as an eye research institute. It offers treatment for macular degeneration, diabetic retinopathy, glaucoma, other types of retinal and optic nerve degenerations and damage, dry eye and eye tissue transplants. The company was founded by Charles L. Schepens in 1950 and is headquartered in Boston, MA.

Massachusetts Eye & Ear Infirmary operates as hospital that provides patient care for disorders of the eye, ear, nose, throat, head and neck. It offers ophthalmology and otolaryngology research services and is a teaching partner of Harvard Medical School. The firm’s programs and services include anesthesiology, ophthalmology, otolaryngology, radiology, Coolidge Clinic laboratory and libraries. The company was founded in 1824 and is headquartered in Boston, MA.

Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Safar Partners LLC (Safar Partners) is a venture capital firm founded in 2019 by Nader Motamedy. The firm is headquartered in Cambridge, Massachusetts.

Claris Biotherapeutics, Inc. engages in the manufacturing of drugs. The company was founded in 2018 and is headquartered in Jersey City, NJ.

GelMEDIX, Inc. operates as a biotechnology technology. The company is headquartered in Newton, MA.

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals.